• Profile
Close

Potential Medicare savings from generic substitution and therapeutic interchange of ACE inhibitors and angiotensin-II-receptor blockers

JAMA Aug 09, 2019

Growdon ME, et al. – Because prescription drug spending accounts for a growing share of US healthcare costs—and spending can be reduced by replacing generic drugs for identical brand-name drugs or for brand-name drugs with similar effect—researchers calculated the potential cost savings for Medicare from generic substitution and therapeutic interchange of ACEIs and ARBs.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay